-
Mashup Score: 13
The goal of surgical resection is to completely remove a cancer; it is useful to have a system to describe how well this was accomplished. This is captured by the residual tumor (R) classification, which is separate from the TNM classification that describes the anatomic extent of a cancer independent of treatment. The traditional R-classification designates as R0 a complete resection, as R1 a macroscopically complete resection but with microscopic tumor at the surgical margin, and as R2 a resection that leaves gross tumor behind.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 21Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 1 month(s) ago
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion, exon 21 L858R), osimertinib remains the standard of care approved by the U.S. Food and Drug Administration in the first-line treatment of EGFR-mutated, advanced NSCLC. Despite continued efforts, disease progression remains inevitable with a high incidence of brain metastasis and poor prognosis for the patients harboring L858R.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 157
R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 157
R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest benefit from postoperative radiation therapy (PORT).
Source: www.jto.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 96Unveiling the Landscape of uncommon EGFR Mutations in Non-Small Cell Lung Cancer - A Systematic Review - 1 month(s) ago
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in these rare mutations is scattered and limited to mostly retrospective small cohorts, as these patients were usually excluded from clinical trials.
Source: www.jto.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 16Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 1 month(s) ago
EGFR accounts for 15% to 50% of nonsquamous, advanced NSCLC. Among various EGFR tyrosine kinase inhibitors (TKIs) designed to target sensitizing mutations (exon 19 deletion, exon 21 L858R), osimertinib remains the standard of care approved by the U.S. Food and Drug Administration in the first-line treatment of EGFR-mutated, advanced NSCLC. Despite continued efforts, disease progression remains inevitable with a high incidence of brain metastasis and poor prognosis for the patients harboring L858R.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 16Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR+ NSCLC - 1 month(s) ago
“Don’t be afraid to give up the good to go for the great.”John D. Rockefeller
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Five-Year Survival Outcomes After Carbon-Ion Radiotherapy for Operable Stage I NSCLC: A Japanese National Registry Study (J-CROS-LUNG) - 2 month(s) ago
The standard therapy for stage I NSCLC is surgery, but some operable patients refuse this option and instead undergo radiotherapy. Carbon-ion radiotherapy (CIRT) is a type of radiotherapy. The Japanese prospective nationwide registry study on CIRT began in 2016. Here, we analyzed real-world clinical outcomes of CIRT for operable patients with stage I NSCLC.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
The Japanese prospective nationwide registry study on CIRT, which began in 2016, studied real-world clinical outcomes of CIRT for operable pts w/stage I #NSCLC. The authors found that this treatment method has favorable outcomes w/tolerable toxicity. https://t.co/YDiOqrArWu #LCSM https://t.co/zR4WimunxM
-
-
Mashup Score: 3
Extensive-stage small cell lung cancer (ES-SCLC) prognosis remains poor. The phase 3 RATIONALE-312 study aimed to evaluate efficacy and safety of tislelizumab plus chemotherapy as first-line treatment for ES-SCLC.
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet-
In the phase 3 RATIONALE-312 study, researchers evaluated efficacy & safety of tislelizumab + chemo as first-line treatment for ES-SCLC. This treatment demonstrated statistically significant clinical benefit & manageable safety compared to placebo + chemo. https://t.co/KTi0h1QtjO https://t.co/8RnVhK23s2
-
-
Mashup Score: 1Lung Cancer in Switzerland - 2 month(s) ago
Currently, 8.7 million people live in Switzerland—a number that has more than doubled in the past 100 years. In the same time, the population has become significantly older, and today, one-fifth is beyond retirement age (65 y in Switzerland). With an average life expectancy of 82 years in men and 86 years in women, Switzerland has one of the highest life expectancies worldwide.1 Annually, 43,000 people are diagnosed with having cancer in Switzerland. The estimated age-standardized lung cancer incidence in Switzerland is lower than that in surrounding countries (Fig. 1).
Source: www.jto.orgCategories: General Medicine News, Onc News and JournalsTweet
This paper represents a comprehensive review of evidence regarding R categories & the descriptors thereof. W/the same overall framework & descriptors in the 9th edition, refinements to the descriptors should facilitate application & further research.https://t.co/Pqc8zM7djK #IASLC https://t.co/M8MHFkSSq3